Tagged with IT

UAE Maher Abouzeid gives his expert insights into the key trends underway in the Middle Eastern medtech industry, including growing numbers of PPPs, the rise of the digital hospital post-COVID, and greater interaction with the pharma sector.   The positive side of COVID is that it helped accelerate the transformation of…

Italy Claudia Coscia outlines how the geographic and portfolio transformation of Kyowa Kirin has played out in Italy in recent years. Coscia also touches on access challenges for rare disease therapies in the Italian pharma market, rising levels of rare disease awareness, and the digitalisation status of the country’s healthcare system. …

USA Ramona Sequeira, recently appointed chair of the PhRMA board of directors and president of Takeda’s US Business Unit and Global Portfolio Commercialization, gives her take on how the biopharma industry can do more to address the systemic inequities in US healthcare, including community-focused grant programs, clinical trial diversity initiatives, and…

Italy Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global…

MEA On International Women’s Day 2022, Inna Nadelwais, executive director at Middle East and Africa medtech trade association Mecomed, examines the road still to travel towards true gender parity in the MEA medtech workforce, and why diversity, inclusion, and equality in the workplace benefits all parties.   The MEA region continues…

Italy Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills, and economic benefits. Here, Italy country managers from some of the world’s leading pharma companies weigh in on the pros…

Italy In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader, post-COVID changes to the pharma industry, and the state of private-public relationships in Europe. Furthermore, d’Alissac touches on the responsibility…

Global Based on analysis from Crunchbase, read on for 2021’s largest VC investments into the biotech industry (which topped USD 65 billion last year) and 2021’s busiest biotech lead investors overall.   Made with Visme Infographic Maker   Made with Visme Infographic Maker

Global As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, contributing to equitable distribution, and driving innovation.   From the early days…

Italy Sanofi’s Country Lead, President & Managing Director for Italy Marcello Cattani discusses his career track and explains the company’s broad manufacturing footprint in the country – where Sanofi has four plants. In addition, he comments on the imminent changes to the Italian healthcare system and how the organization is transforming…

Global Two years into his role, Ipsen’s EVP and Chief Medical Officer Prof. Dr. med. Steven Hildemann MD discusses his vision of patient-centricity and how he is leading a medical transformation that puts data-driven insights at the core and aims to make a real difference to both clinical practice and patients’…

UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…